Pharmacoeconomic analysis of trastuzumab application for subcutaneous administration compared to intravenous administration in the treatment of HER2-positive breast cancer in regions of the Russian Federation

Pharmacoeconomic Analysis ◽

Subcutaneous Administration ◽

Her2 Positive ◽

The Russian Federation ◽

Pharmacoeconomic analysis of kadcyla (trastuzumab emtansine) in the treatment of patients with her2-positive breast cancer

Pharmacoeconomics theory and practice ◽

10.30809/phe.2.2015.9 ◽

2015 ◽

Vol 3 (2) ◽

pp. 28-31

Author(s):

A.Yu. Kulikov ◽

I.A. Komarov

Keyword(s):

Breast Cancer ◽

Pharmacoeconomic Analysis ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer

The Journal of Clinical Pharmacology ◽

10.1177/0091270012436560 ◽

2013 ◽

Vol 53 (2) ◽

pp. 192-201 ◽

Cited By ~ 63

Author(s):

Chris Wynne ◽

Vernon Harvey ◽

Christian Schwabe ◽

Devonie Waaka ◽

Christine McIntyre ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Healthy Male ◽

Her2 Positive ◽

Healthy Male Volunteers ◽

Male Volunteers ◽

Safety Assessment of Intravenous Administration of Trastuzumab in 100ml Saline for the Treatment of HER2-Positive Breast Cancer Patients

Asian Pacific Journal of Cancer Prevention ◽

10.7314/apjcp.2013.14.8.4843 ◽

2013 ◽

Vol 14 (8) ◽

pp. 4843-4846 ◽

Cited By ~ 1

Author(s):

Hajime Abe ◽

Tsuyoshi Mori ◽

Yuki Kawai ◽

Kaori Tomida ◽

Keiichi Yamazaki ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Safety Assessment ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer

Journal of Comparative Effectiveness Research ◽

10.2217/cer-2017-0048 ◽

2018 ◽

Vol 7 (5) ◽

pp. 411-419 ◽

Cited By ~ 4

Author(s):

Jens Olsen ◽

Kenneth Forsstrøm Jensen ◽

Daniel Sloth Olesen ◽

Ann Knoop

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

Review of treatment strategies for HER2 positive breast cancer and their implementation in a major Swiss hospital

10.1055/s-0040-1710671 ◽

2020 ◽

Author(s):

F Geissler ◽

M Vetter ◽

A Schoetzau ◽

C Montavon ◽

C Kurzeder ◽

...

Keyword(s):

Breast Cancer ◽

Treatment Strategies ◽

Her2 Positive ◽

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis

10.26226/morressier.596dfd55d462b80292386fa4 ◽

2017 ◽

Author(s):

You-Jeong Seo

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Sequential Analysis ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Pik3ca Mutations ◽

Hypoxia up-regulates ID proteins in Luminal and HER2-positive breast cancer cell lines

10.26226/morressier.5b4709836f4cb30010951ad8 ◽

2018 ◽

Author(s):

Gloria Peiro Cabrera

Keyword(s):

Breast Cancer ◽

Cell Lines ◽

Cancer Cell ◽

Breast Cancer Cell ◽

Breast Cancer Cell Lines ◽

Her2 Positive ◽

Id Proteins ◽

Positive Breast Cancer Cell ◽

FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer

Case Medical Research ◽

10.31525/cmr-24bd324 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Her2 Positive ◽

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies

Case Medical Research ◽

10.31525/cmr-24bb59f ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Treatment Option ◽

Her2 Positive ◽

New Treatment ◽

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies

Case Medical Research ◽

10.31525/cmr-24bb467 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Treatment Option ◽

Her2 Positive ◽

New Treatment ◽